Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q4 FY26 results · Jan–Mar 2026
Aarti Drugs reported revenue from operations of ₹720.30 crore (up 6.4% from Q4 FY25) and net profit of ₹55.26 crore (down 12.0% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 720.30 | 676.76 | +6.4% | 601.71 | +19.7% |
| Other income | 0.76 | 1.87 | −59.4% | 1.23 | −38.2% |
| Total income | 721.06 | 678.63 | +6.3% | 602.94 | +19.6% |
| Profit before tax | 70.36 | 71.15 | −1.1% | 29.02 | +142.5% |
| Net profit for the period | 55.26 | 62.77 | −12.0% | 40.55 | +36.3% |
| Attributable to shareholders of the company | 55.19 | 62.86 | −12.2% | 40.54 | +36.1% |
| EPS, basic (₹) | 6.05 | 6.88 | −12.1% | 4.44 | +36.3% |
| Net margin (%) | 7.7 | 9.3 | 6.7 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 631.68 | 622.96 | +1.4% | 528.80 | +19.5% |
| Other income | 0.83 | 1.71 | −51.5% | 1.22 | −32.0% |
| Total income | 632.51 | 624.67 | +1.3% | 530.02 | +19.3% |
| Profit before tax | 58.56 | 70.67 | −17.1% | 21.71 | +169.7% |
| Net profit for the period | 44.96 | 61.48 | −26.9% | 33.84 | +32.9% |
| EPS, basic (₹) | 4.93 | 6.74 | −26.9% | 3.71 | +32.9% |
| Net margin (%) | 7.1 | 9.9 | 6.4 |
Consolidated
- Filed with BSE
- 15 May 2026, 21:13 IST
- Board meeting
- 15 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 May 2026, 21:13 IST
- Board meeting
- 15 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE